Lmr Partners LLP Nektar Therapeutics Transaction History

Lmr Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.17 - $6.17 $194,263 - $378,109	-61,282 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.16 - $13.72 $20,546 - $67,763	-4,939 Reduced 7.46%	61,282 $330,000
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $717,173 - $1.22 Million	66,221 New	66,221 $895,000
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $2.55 Million - $4.92 Million	-175,961 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $2.79 Million - $4.07 Million	175,961 New	175,961 $3.8 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $379,918 - $707,275	-12,485 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $5.49 Million - $8.09 Million	-118,125 Reduced 90.44%	12,485 $761,000
Q2 2018 Aug 03, 2018	BUY	$46.25 - $104.45 $6.04 Million - $13.6 Million	130,610 New	130,610 $6.38 Million

16.1M

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $11.8B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.